InflaRx presents kidney data. Needham sets USD 8.00 target for InflaRx stock

Published on 10/18/2026 at 13:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

InflaRx will present izicopan data on October 22, 2026. InflaRx stock has a USD 8.00 Needham target and 90.00 percent blockade.

Izicopan milestones and targets

InflaRx scheduled an izicopan poster for October 22, 2026.
Izicopan achieved at least 90.00 percent C5a blockade over 14 days.
Needham set an USD 8.00 price target on September 14, 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx N.V. (ISIN NL0012661870) will present late-breaking izicopan data at Kidney Week on October 22, 2026, after reported studies showed at least 90.00 percent blockade of C5a-induced neutrophil activation over 14 days. According to Yahoo Finance, the late-breaking poster will cover izicopan, an oral C5a receptor antagonist, at the American Society of Nephrologys meeting in Denver.

Kidney Week sets the next test

The October 2, 2026 announcement gives investors a concrete clinical milestone rather than a scheduled financial update. The poster session is set for October 22, 2026 from 10:00 a.m. to 12:00 p.m. ET, and the presentation will focus on kidney disease models.

The evidence cited in the release spans several stages of development. First-in-human studies reported no safety signals of concern across single doses from 3 mg to 240 mg and multiple doses from 30 mg once per day to 90 mg twice per day for 14 days. Topline Phase 2a data also supported the safety profile, while studies in hidradenitis suppurativa and chronic spontaneous urticaria supplied additional efficacy context.

What does the target imply?

Needham initiated coverage with a Buy rating and an USD 8.00 price target on September 14, 2026, according to MarketBeat. The same report listed Cantor Fitzgerald raising its target from USD 4.00 to USD 6.00 on August 7, 2026, while Zacks Research cut its rating to Hold on August 25, 2026. The figures show a wide range of views around a development-stage biotech.

Leadership and financial footing

InflaRx appointed Gabriela Alperovich as Senior Vice President and Global Head of Clinical Development effective October 1, 2026. BiopharmaWatch reported that she brings more than 20 years of pharmaceutical experience, including renal and immune-inflammatory programs. InflaRx reported a quarterly loss of USD 0.11 per share for the quarter covered in its August 7, 2026 results, missing the cited USD 0.07 consensus loss by USD 0.04, according to MarketBeat.

Dates for the clinical pipeline

The next dated event is the Kidney Week poster on October 22, 2026. The companys investor-relations calendar also lists its virtual Capital Markets Day on September 21, 2026, while its second-quarter 2026 results were published on August 6, 2026.

Clinical data now define the setup

For InflaRx, the October 22 presentation connects the 90.00 percent pharmacodynamic result with the companys next development step. The USD 8.00 Needham target and the competing analyst calls provide valuation context, but the poster remains the next company-specific date for the izicopan program. The further course of trading is shown by the continuously updated real-time quote of InflaRx stock.